Last update 12 Dec 2024
Megestrol Acetate
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate, 17alpha-Acetoxy-6-dehydro-6-methylprogesterone + [36] |
Target |
Mechanism PR agonists(Progesterone receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Aug 1971), |
RegulationOrphan Drug (US) |
Login to view timeline
Structure
Molecular FormulaC24H32O4 |
InChIKeyRQZAXGRLVPAYTJ-GQFGMJRRSA-N |
CAS Registry595-33-5 |
Related
84
Clinical Trials associated with Megestrol AcetateEvaluation of the safety and efficacy of megestrol acetate plus mirtazapine in combination versus megestrol acetate alone in cachexia induced by GI cancers
PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer
Phase III Study on the Relation of Nutrition and Immunotherapy of Cancer Patients
100 Clinical Results associated with Megestrol Acetate
Login to view more data
100 Translational Medicine associated with Megestrol Acetate
Login to view more data
100 Patents (Medical) associated with Megestrol Acetate
Login to view more data
2,026
Literatures (Medical) associated with Megestrol Acetate01 Dec 2024GYNECOLOGIC ONCOLOGY
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study
Article
Author: Fleming, Nicole D ; Meyer, Larissa A ; Nassif Haddad, Elise F ; Soliman, Pamela T ; Saab, Reem ; Ratan, Ravin ; Legarreta, Alejandra Flores ; Nassif Haddad, Elise F. ; Fellman, Bryan M. ; Soliman, Pamela T. ; Frumovitz, Michael ; Fellman, Bryan M ; Fleming, Nicole D. ; Meyer, Larissa A.
OBJECTIVE:
To evaluate the disease course of patients with low grade endometrial stromal sarcoma (LG-ESS) and compare oncologic outcomes associated with hormonal therapy in primary and recurrent disease.
METHODS:
This is a retrospective study of patients with LG-ESS who underwent active treatment between January 2000 and July 2023. Recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier product-limit estimator and modeled via Cox proportional hazards regression.
RESULTS:
A total of 221 patients were included; 58 % of patients (91/157) were stage I, 12 % (19/157) stage II, 13 % (20/157) stage III, and 17 % (27/157) stage IV. Surgery was the primary treatment for 98 % (213/218). Only 79 patients received hormonal adjuvant therapy, 58 % (46/79) Megace, 24 % (19/79) Letrozole, and 18 % (14/79) received other hormonal therapy. There was no significant difference in RFS (p = 0.159) and OS (p = 0.167) between patients receiving Megace versus Letrozole as adjuvant therapy. At first recurrence, patients given Megace had a similar RFS to those on Letrozole (p = 0.302), but a better OS (27 vs 10 months, p = 0.018). Negative status of estrogen, smooth muscle actin, and desmin were associated with lower RFS (p = 0.039, p = 0.002, and p = 0.015, respectively) and OS (p = 0.008, p = 0.012, and p = 0.013, respectively). Lymphovascular invasion was associated with lower RFS (p = 0.033), and negative status of progesterone was associated with lower OS (p = 0.003).
CONCLUSION:
There was no difference in oncologic outcomes between Megace and Letrozole in patients who received adjuvant therapy for LG-ESS. Megace may have potential survival advantage in recurrent disease. Further study is warranted to determine the most effective agents and their sequence in the treatment of LG-ESS.
20 Nov 2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].
Article
Author: Bai, Jing ; Chu, Danxia ; Lai, Tianjiao ; Yan, Shuping ; Guo, Ruixia ; Wang, Yuanyuan ; Qin, Haixia
OBJECTIVE:
To evaluate the efficacy of medroxyprogesterone acetate (MA) plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and early-stage grade 1 endometrial adenocarcinoma (G1 EAC) and the recurrence rate after treatment.
METHODS:
Sixty patients (aged 20-42 years) with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups (n=30) to receive oral MA treatment at the daily dose of 160 mg (control) or MA plus oral metformin (850 mg, twice a day) for at least 6 months. The treatment could extend to 12 months until a complete response (CR) was achieved, and follow-up hysteroscopy and curettage were performed every 3 months. For all the patients who achieved CR, endometrial expressions of IGFBP-rP1, p-Akt and p-AMPK were detected immunohistochemically.
RESULTS:
A total of 58 patients completed the treatment. After 9 months of treatment, 23 (76.7%) patients in the combined treatment group and 20 (71.4%) in the control group achieved CR; two patients in the control group achieved CR after converting to the combined treatment. The recurrence rate did not differ significantly between the control group and combined treatment group (30.0% vs 22.7%, P>0.05). Ten (35.7%) patients in the control group experienced significant weight gain of 5.7±6.1 kg, while none of the patients receiving the combined treatment exhibited significant body weight changes. Compared with the control group, the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.
CONCLUSION:
Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC, and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.
01 Nov 2024Immunity Inflammation and Disease
Identification of Vesicle‐Mediated Transport‐Related Genes for Predicting Prognosis, Immunotherapy Response, and Drug Screening in Cervical Cancer
Article
Author: Lv, Hongqing ; Zhang, Lin ; Lou, Shuai
ABSTRACT:
Background:
Cervical cancer is one of the most common malignancies among women. Vesicle‐mediated transport mechanisms significantly influence tumor cell behavior through intercellular material exchange. However, prognostic significance in CC patients remains underexplored.
Research Design and Methods:
We identified differentially expressed vesicle‐mediated transport‐related genes from TCGA and GeneCards datasets through differential expression analysis. We constructed a prognostic model using Cox regression and LASSO regression, categorized patients into high‐ and low‐risk groups, and validated the model in the GEO data set. A nomogram integrating clinical features and risk scores demonstrated the model's independent prognostic capability. We analyzed tumor immune cell infiltration, immune checkpoints, and predicted immunotherapy responses in the high‐ and low‐risk groups. Finally, we screened potential drugs for targeting CC and conducted drug‐sensitivity analysis.
Results:
We successfully established a 10‐gene prognostic model based on VMTRGs. The low‐risk group exhibited favorable prognosis, significant immune cell infiltration, and promising immunotherapy response, whereas the high‐risk group showed higher sensitivity to chemotherapeutic agents such as Docetaxel and Paclitaxel. Potential drugs identified for targeting CC patients included Megestrol acetate, Lenvatinib, Adavosertib, and Barasertib.
Conclusions:
The VMTRG‐based prognostic model demonstrates reliable clinical prognostic value and enhances understanding of vesicle‐mediated transport mechanisms in CC.
100 Deals associated with Megestrol Acetate
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Acquired Immunodeficiency Syndrome | US | 18 Aug 1971 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dementia | Phase 3 | ES | 01 Jun 2007 | |
| Neoplasms | Phase 3 | US | 01 Jun 2006 | |
| Anorexia | Phase 3 | US | 31 Aug 2001 | |
| Cachexia | Phase 3 | US | 31 Aug 2001 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | ES | 01 Oct 2006 | |
| HIV Wasting Syndrome | Phase 2 | US | 01 Dec 2004 | |
| HIV Wasting Syndrome | Phase 2 | IN | 01 Dec 2004 | |
| HIV Wasting Syndrome | Phase 2 | ZA | 01 Dec 2004 | |
| Malnutrition | Phase 2 | US | 31 Aug 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | - | beryalhmlk(xnrwuvargg) = grwxbegopy gjvuscjzsf (rlrdjskpak ) View more | Positive | 31 Aug 2024 | |||
beryalhmlk(xnrwuvargg) = grtparabos gjvuscjzsf (rlrdjskpak ) View more | |||||||
Not Applicable | - | olikbqoysd(frsrmziqsg) = fmslqlldvd fsqplluzps (coisfdaknc ) View more | - | 24 May 2024 | |||
Phase 2 | Estrogen receptor positive breast cancer ER+ | HER2- | 20 | Megestrol-Acetate (MA) | kywogtlbax(bvqsiqtpir) = uyibunpnrm uefkdagaxu (cinbzpnxvz ) View more | Negative | 12 May 2023 | |
Another Hormone Therapy (AHT) | kywogtlbax(bvqsiqtpir) = gbcycfmnxs uefkdagaxu (cinbzpnxvz ) View more | ||||||
Not Applicable | Endometrial Carcinoma estrogen receptor | progesterone receptors | 83 | Tamoxifen-progestin combination therapy | bhcgdnowva(msbbossgpc) = nhzpashqsf fgbhsbpzrk (lzdvbdapof ) | Positive | 20 Oct 2022 | |
Progestin-only therapy | bhcgdnowva(msbbossgpc) = kiphjtdeml fgbhsbpzrk (lzdvbdapof ) | ||||||
Phase 2 | 150 | (Megestrol Acetate and Metformin) | upzzxpogvc(kxkmydqkpj) = bdzaxhzqwu alluwwlnam (ywmmkrxlch, vkvrqvsrmx - ejbwxcmnyy) View more | - | 13 Sep 2021 | ||
(Megestrol Acetate) | upzzxpogvc(kxkmydqkpj) = soajcxybgb alluwwlnam (ywmmkrxlch, tfmupixhjh - owcacnvsop) View more | ||||||
Phase 2 | 9 | Quality-of-Life Assessment+megestrol acetate (Regimen 1 (Megestrol Acetate, Surgery)) | tbdhgitxfl(ngsejdncsm) = wccuuhfabj nwhnobfvpj (dawptztfhj, jnojynssgx - elvwxaqzzg) View more | - | 14 Oct 2020 | ||
Quality-of-Life Assessment+megestrol acetate (Regimen 2 (Megestrol Acetate, Surgery)) | tbdhgitxfl(ngsejdncsm) = mnsabysoph nwhnobfvpj (dawptztfhj, pjshkcnsjj - aghuwjntaf) View more | ||||||
Not Applicable | 150 | Megestrol acetate (MA) | jlujcnavcp(aabbezkxoo) = gdrrvscayx pzvznmkcgm (qjbssnwlbz ) View more | Positive | 18 Sep 2019 | ||
Megestrol acetate (MA) plus metformin | jlujcnavcp(aabbezkxoo) = jdcrbmmuqk pzvznmkcgm (qjbssnwlbz ) View more | ||||||
Phase 4 | 21 | (Phenytoin, Then Megestrol) | mvrccipjya(rtwucnumxu) = dnoyhgnfna ywyntdnsjq (lwbzhpiivt, lbpyvkzydc - ndfrxjuaov) View more | - | 09 Sep 2019 | ||
Phenytoin-matched Placebo capsule+Megestrol 800 mg liquid (Placebo, Then Megestrol) | mvrccipjya(rtwucnumxu) = wiyfsmxcvq ywyntdnsjq (lwbzhpiivt, nitblcdufr - mhommbtegw) View more | ||||||
Phase 2 | - | 21 | (Amitriptyline, Megestrol) | dmtihrthnh(jhrkmnwynd) = numatkgntb tnsbludbee (rapauxeogx, rppsdrsazy - huexwprrhy) View more | - | 15 Aug 2016 | |
Placebo+Megestrol (Placebo, Megestrol) | dmtihrthnh(jhrkmnwynd) = ubamenovir tnsbludbee (rapauxeogx, fottkcecfv - wabahlajmc) View more | ||||||
Phase 3 | 4 | (DB MA-CS 550 mg/Day) | rlnxmhvedf(fnimwrcyje) = jvpfbzctdv hvghlzpsyn (nirnivlkwk, fihiwzaufn - fpaxaryklp) View more | - | 02 May 2016 | ||
DB MA-CS (DB MA-CS 300 mg/Day) | rlnxmhvedf(fnimwrcyje) = osdkmxiaxp hvghlzpsyn (nirnivlkwk, yephhyjagj - wrazsbmfve) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free